What does Alcon Inc. do?

Alcon (NYSE and Swiss exchange SIX: ALC) is the world's #1 company fully dedicated to eye care. It was born in Fort Worth, Texas, in 1945 (from a two-partner pharmacy: Alexander and Conner), belonged to Nestlé and then Novartis, and became an independent public company in April 2019. It has two businesses: (1) Surgery (~54% of sales) — the heart of the company: Cataract surgery equipment: the machines (phacoemulsification systems; the new UNITY platform) a surgeon uses to remove the lens clouded by the cataract. Intraocular lenses: the artificial lens implanted in that eye. Its stars are PanOptix and PanOptix Pro (they correct both near and far vision) and Vivity. Plus equipment for retina and refractive surgery. (2) Vision (~46% of sales) — the consumer business: Contact lenses: Precision1, Total30, Dailies. Eye health: dry-eye drops Systane (market leader) and Tryptyr, a new prescription for dry eye. Why it's a quality business: everyone's eyes age — cataracts are practically inevitable with age — the world performs more than 20 million cataract surgeries a year, and between them Alcon and Johnson & Johnson control ~50% of the equipment market for that surgery. It's specialized medical equipment where the surgeon trusts the brand and doesn't switch lightly. Leadership: CEO David J. Endicott (since it became independent in 2019). HQ in Geneva, Switzerland, with a large operating center in Fort Worth, Texas. ~25,600 employees.

Why did Vectorial Data pick ALC?

ALC at $66.40 is buying the world leader in eye care after a sharp drop — from ~$92 to ~$66 — whose causes are already behind it. Concrete reasons: 1. The valuation reset and the 'expensive P/E' is a mirage. At ~40 times accounting profit it looks expensive, but that number is inflated by a charge that isn't real money: the amortization of old acquisitions (~$696 million a year, a legacy of when it was split off from Novartis). On its true earnings ('core' profit of $3.07 per share, growing 10-13%) it trades at ~17 times — the cheapest it's been since it went public in 2019. 2. The bad news has already passed. The two blows that sank the stock — the mid-2025 target cut and the failed STAAR acquisition in January 2026 — are already in the past. The drop was driven by headlines, not because the business stopped working. 3. The business never broke. In Q1 2026 (reported May 6) sales grew +10% to $2.7 billion, adjusted profit +16%, and the company raised its profit-growth target for the year to +10-13%. That is not a company in trouble. 4. A nearly guaranteed demographic tailwind. The population over 60 will double by 2050, and cataracts come with age. Demand for surgeries and lenses only rises over time. 5. A wave of new products. Right now it's launching its UNITY platform, PanOptix Pro, the Tryptyr drop, and Valeda (for a retina disease) — several levers to beat already-lowered expectations. 'Buy' rating, average target ~$87 (~+31% from $66.40). It reports on August 10.

What are the risks of investing in ALC?

Risks: (1) Weaker cataract surgeries — the #1: that's exactly what triggered the 2025 target cut, and surgery is 54% of sales; if operation volumes don't recover, the thesis gets delayed. (2) Competition: Alcon and Johnson & Johnson split ~50% of the cataract market, but in contact lenses it's losing ground to CooperVision and J&J, and in surgery it competes with Bausch+Lomb and Zeiss. (3) U.S. tariffs: even though Alcon already lowered its assumption to 10%, it's still a live cost in 2026. (4) Currency exchange: it's a Swiss company that reports in dollars; currency swings move its numbers (in Q1 there were 4 points of difference between the 'real' growth and the reported growth). (5) Launch execution: the thesis rests on UNITY, PanOptix Pro, Tryptyr, and Valeda taking off; if they're delayed, the ghost of the target cut returns. And the dividend (~0.5%) is so small that it offers almost no cushion if the stock falls.

Does ALC pay dividends?

Yes. Alcon Inc. pays a dividend of about 0.53% per year.

How can I buy ALC with little money?

You can buy fractional shares of ALC starting from a few dollars with any broker that offers fractional shares. The Vectorial Data method: invest the same amount in every pick, every time.

When was this ALC analysis last updated?

The ALC analysis was last updated on Invalid Date.

Stocks/ALC

ALC — Alcon Inc.

HealthcareEuropeSwitzerlandBlockchain certified

$66.40

Target: $87.00 (+31%)

P/E Ratio

39.8

P/E Forward

16.7

Dividend

0.53%

Market Cap

$32.8B

EPS

$1.67

Consensus

Buy

What they do

Alcon (NYSE and Swiss exchange SIX: ALC) is the world's #1 company fully dedicated to eye care. It was born in Fort Worth, Texas, in 1945 (from a two-partner pharmacy: Alexander and Conner), belonged to Nestlé and then Novartis, and became an independent public company in April 2019. It has two businesses:

Surgery (~54% of sales)** — the heart of the company:
Cataract surgery equipment: the machines (phacoemulsification systems; the new UNITY platform) a surgeon uses to remove the lens clouded by the cataract.
Intraocular lenses: the artificial lens implanted in that eye. Its stars are PanOptix and PanOptix Pro (they correct both near and far vision) and Vivity.
Plus equipment for retina and refractive surgery.

Vision (~46% of sales)** — the consumer business:
Contact lenses: Precision1, Total30, Dailies.
Eye health: dry-eye drops Systane (market leader) and Tryptyr, a new prescription for dry eye.

Why it's a quality business: everyone's eyes age — cataracts are practically inevitable with age — the world performs more than 20 million cataract surgeries a year, and between them Alcon and Johnson & Johnson control ~50% of the equipment market for that surgery. It's specialized medical equipment where the surgeon trusts the brand and doesn't switch lightly.

Leadership: CEO David J. Endicott (since it became independent in 2019). HQ in Geneva, Switzerland, with a large operating center in Fort Worth, Texas. ~25,600 employees.

Why we like it

ALC at $66.40 is buying the world leader in eye care after a sharp drop — from ~$92 to ~$66 — whose causes are already behind it. Concrete reasons:

The valuation reset and the 'expensive P/E' is a mirage. At ~40 times accounting profit it looks expensive, but that number is inflated by a charge that isn't real money: the amortization of old acquisitions (~$696 million a year, a legacy of when it was split off from Novartis). On its true earnings ('core' profit of $3.07 per share, growing 10-13%) it trades at ~17 times — the cheapest it's been since it went public in 2019.

The bad news has already passed. The two blows that sank the stock — the mid-2025 target cut and the failed STAAR acquisition in January 2026 — are already in the past. The drop was driven by headlines, not because the business stopped working.

The business never broke. In Q1 2026 (reported May 6) sales grew +10% to $2.7 billion, adjusted profit +16%, and the company raised its profit-growth target for the year to +10-13%. That is not a company in trouble.

A nearly guaranteed demographic tailwind. The population over 60 will double by 2050, and cataracts come with age. Demand for surgeries and lenses only rises over time.

A wave of new products. Right now it's launching its UNITY platform, PanOptix Pro, the Tryptyr drop, and Valeda (for a retina disease) — several levers to beat already-lowered expectations. 'Buy' rating, average target ~$87 (~+31% from $66.40). It reports on August 10.

Key Risk

Risks:

Weaker cataract surgeries — the #1: that's exactly what triggered the 2025 target cut, and surgery is 54% of sales; if operation volumes don't recover, the thesis gets delayed.
Competition: Alcon and Johnson & Johnson split ~50% of the cataract market, but in contact lenses it's losing ground to CooperVision and J&J, and in surgery it competes with Bausch+Lomb and Zeiss.
U.S. tariffs: even though Alcon already lowered its assumption to 10%, it's still a live cost in 2026.
Currency exchange: it's a Swiss company that reports in dollars; currency swings move its numbers (in Q1 there were 4 points of difference between the 'real' growth and the reported growth).
Launch execution: the thesis rests on UNITY, PanOptix Pro, Tryptyr, and Valeda taking off; if they're delayed, the ghost of the target cut returns. And the dividend (~0.5%) is so small that it offers almost no cushion if the stock falls.

This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.

Vectorial Data picked ALC on 2026-07-23 at $66.40.

Last updated: Invalid Date

Dividends received by the Vectorial portfolio

ALC has not paid a dividend to the portfolio yet.

Full Research

Alcon (ALC) — Research Completo

Precio: $66.40 | P/E TTM: ~40x (contable) / ~17x (core) | Div Yield: ~0.5% | Market Cap: ~$32.8 mil millones USD

¿Qué es Alcon?

La empresa #1 del mundo dedicada por completo al cuidado de los ojos. Fundada en Fort Worth, Texas, en 1945 (de la farmacia de Alexander y Conner). Pasó por Nestlé y Novartis, y se independizó en bolsa en abril de 2019. HQ hoy en Ginebra, Suiza; cotiza en Nueva York (NYSE) y en la bolsa suiza (SIX). CEO David J. Endicott (desde el spin-off de 2019). ~25,600 empleados.

Los 2 negocios (Q1 2026)

Segmento	% ventas	Qué es	Ventas Q1 2026
Cirugía	~54%	Equipos de cirugía de cataratas (UNITY), lentes intraoculares (PanOptix, Vivity), retina, refractiva	$1.46 mil millones (+10%)
Visión (Vision Care)	~46%	Lentes de contacto (Precision1, Total30, Dailies) + salud ocular (Systane, Tryptyr)	$1.23 mil millones (+9%)

Último trimestre (Q1 2026, reportado 6 may 2026)

Métrica	Q1 2026
Ingresos	$2.7 mil millones (+10% reportado / +6% en moneda constante)
EPS core (ajustado)	$0.85 (+16%), superó lo esperado
Guía 2026	Ventas +5-7%; utilidad core subida a +10-13%

FY2025: ingresos ~$10.4 mil millones; utilidad core por acción $3.07. Próximo reporte: ~10 de agosto de 2026 (consenso ~$2.76 mil millones).

Por qué cayó de ~$92 a ~$66

No fue un golpe único, sino una serie de decepciones a lo largo de un año:

Recorte de meta a mediados de 2025: bajó su meta de ventas del año (a +4-5% desde +6-7%) por cirugías de catarata más flojas, pérdida de algo de participación y aranceles de EE.UU.. La acción cayó ~11-12% ese día; varias casas la bajaron de calificación.
Se cayó la compra de STAAR Surgical: en agosto de 2025 Alcon acordó comprar STAAR (lentes implantables para corregir la vista) por ~$28-30.75 por acción, pero los accionistas de STAAR la rechazaron el 6 de enero de 2026 y Alcon canceló el trato. Le quitó una pata de crecimiento esperada.
BofA la bajó a 'Underperform' tras el fracaso del trato, con precio objetivo de $75.

El resultado: el múltiplo se comprimió aunque los ingresos seguían creciendo a doble dígito.

El punto clave de valuación: el 'PE caro' es un espejismo

El P/E contable de ~40 asusta, pero está inflado por ~$696 millones al año de amortización de intangibles —un cargo contable que no es salida de dinero, herencia de las compras viejas y de la separación de Novartis—. Si miras las ganancias de verdad (utilidad core de $3.07 por acción, creciendo 10-13%), el P/E baja a ~17 veces: lo más barata que ha estado desde 2019.

Anchor Fact

El mundo hace más de 20 millones de cirugías de catarata cada año, y entre Alcon y Johnson & Johnson fabrican cerca de la mitad de los equipos y lentes que se usan en ellas — es decir, la tecnología de Alcon está en el quirófano de unos ~10 millones de operaciones que le devuelven la vista a la gente cada año. Y como las cataratas llegan con la edad, y la población mayor de 60 se duplicará hacia 2050, la demanda es una de las más predecibles de toda la medicina.

Top 5 Riesgos

Cirugías de catarata flojas — fue lo que causó el recorte de 2025; la cirugía es el 54% de las ventas
Competencia — Cooper/J&J en lentes de contacto; Bausch+Lomb/Zeiss en cirugía
Aranceles de EE.UU. — costo vivo en 2026 aun al 10% supuesto
Tipo de cambio — empresa suiza que reporta en dólares
Ejecución de lanzamientos — UNITY, PanOptix Pro, Tryptyr, Valeda deben despegar; dividendo (~0.5%) da poco colchón

Consenso de analistas

Rating: Buy / Overweight (~22 Buy / 3 Hold / 1 Sell)
Target promedio: ~$87 (~+31% desde $66.40); rango $66-$107

Tesis en una línea

El líder mundial del cuidado de los ojos, en oferta tras dos sustos ya superados: el negocio crece a doble dígito, la valuación real es ~17x, y la demografía del envejecimiento le garantiza clientes por décadas.

Research fecha: 23 Jul 2026 | Próxima revisión: Ene 2027

Esto no es asesoría financiera.

More picks in Healthcare

See all Healthcare picks →

More picks from Switzerland

See all picks from Switzerland →

Researched: 7/23/2026Updated: 7/23/2026Next review: 1/23/2027

This is not financial advice. Consult a certified financial advisor.

The author may hold positions in the securities discussed.

Past performance does not guarantee future results.